SECTION. Stem Cell Therapy Potential of Stem Cell Banking in India

Size: px
Start display at page:

Download "SECTION. Stem Cell Therapy. 170. Potential of Stem Cell Banking in India"

Transcription

1 SECTION 21 Stem Cell Therapy 170. Potential of Stem Cell Banking in India

2

3 170 CHAPTER Potential of Stem Cell Banking in India Vinod K Shah, Kavita K Shalia INTRODUCTION India has not only made great progress along with the world in stem cell basic research but has also made advances in understanding on how to use these cells for treating various diseases. Here, the requirement of stem cell bank with guidelines from regulatory bodies becomes an essential to provide standard material for research and good manufacturing practice (GMP)/ good laboratory practice (GLP) compliant cell-based product for therapy. The upcoming feature in this area is umbilical cord blood (UCB) banks. UCB banking has improved with time largely due to involvement of professional organizations and their published standards. However, accreditation of these organizations remains voluntary, and in India three of ten banks are public with the remaining being private. Public policy regarding UCB is in its infancy throughout most of the world. The potential of stem cell banks can be tapped by initiating an awareness campaign and a customized marketing plan. Stem cells are the basic building blocks of life. They are found in the body s organs, tissues, blood and immune system, and have the ability to regenerate into additional stem cells or differentiate into specialized cells, such as nerve or blood cells. The adult stem cell s job is to regenerate and repair tissue. Every time our body heals itself from a cut or injury that is the healing power of adult stem cells working inside us. It is the self-healing power of the adult stem cell which offers scientists the possibility of a creating new therapies and cures for a wide variety of diseases. 1-3 In the field of stem cell biology, basic research and rapid movement toward translational research and eventually to clinical practice is on parallel run. For successful use of stem cells in clinical practice, there are several areas that need to be looked at, such as efficacy, safety, toxicity, delivery routes and techniques, to ensure that the cell type used is safe and efficacious to conduct human clinical trials. But the most important is to select the tissue source and the type of stem cells or differentiated cells that possess the greatest potential for curing a specific disease. If all these criteria are met with success, it would be easier to obtain regulatory approvals that are required for effective translation of use of stem cells from bench-to-bedside. Thus the development of clinical-grade cell-based therapeutics is a challenging process due to their specific and complex nature, high innovation level combined with rapid developmental boost and recent implementation of severe regulations. According to these newly introduced regulatory standards, the manufacturing of cell-based products must be fully GMP/GLP compliant with a rigorous GMP quality control, fulfilling all pharmaceutical requirements for medicinal products. This begins already at the choice of starting raw material and goes all the way to release of the final product by the qualified person. The costly GMP/GLP facilities, the manufacturing license and the firm quality assurance systems are now defined as prerequisite for development and manufacturing of cell-based products. STEM CELL BANK Stem cell bank, a repository for all types of stem cells, i.e. cord blood, adult and embryonic resolves the issue of obtaining standardized cells/research materials for comparison and reproducibility of results in basic research as well as in its therapeutic applications. Parameters for quality control procedure in the stem cell bank are checking of chromosomal abnormalities, testing of infectious diseases such as human immunodeficiency virus (HIV) I & L, human T-lymphotropic virus (HTLV), hepatitis C virus (HCV), hepatitis B surface antigen (HBS Ag), cytomegalovirus (CMV) ability of stem cells to undergo freeze-thawing processes, immune compatibility of the stem cells with patients potentially requiring the cells, presence of viruses within the stem cells that may cause disease, ability of

4 1096 SECTION 21: Stem Cell Therapy the stem cells to give rise to the required adult cell types when required and ability of the stem cell numbers to be increased to useful amounts. While the banking of hematopoietic stem cells (HSCs) from different sources (bone marrow, cord blood) is already a well-established and standard procedure, there is less experience with other cell types, e.g. mesenchymal stem cells (MSCs) and their intermediate products. 4 CORD BLOOD CELLS AND CORD BLOOD BANK One of the scientifically and clinical most promising raw material is certainly umbilical cord (UC) or UCB. It has been shown to be a viable alternative to bone marrow and peripheral blood and has clear advantages over the other sources of stem cells. It requires less restriction for matching, as the naive immune system appears to cause less severe graft-versus-host disease (GVHD). Since the first successful transplant in a child with Fanconi anemia in 1988, UCB has emerged as a feasible alternative source of hematopoietic progenitor/stem cells for allogeneic transplantation. 5 It is used to treat a variety of oncologic, genetic, hematologic and immunodeficiency disorders when a human leukocyte antigen (HLA)-matched adult donor is not available. 6,7 To date, more than 10,000 patients worldwide have received a UCB transplant. Additionally, several investigational human trials involving cell types derived from UCB have been initiated. 6-8 As the clinical utility turn out to be apparent, collection and banking of UCB became more widespread all over the world. 9 The first unrelated UCB bank was started at the New York Blood Center in 1992 and has the highest inventory of 48,808 UCB. The expansion of UCB banking has led to the establishment of UCB quality standards by professional groups such American Association of Blood Banks (AABB) and the Foundation for Accreditation of Cellular Therapy (FACT/NetCord). 10,11 These best-practice expectations pertain to collect, process, test (e.g. HLA typing, infectious disease testing) and cryopreserve UCB for potential future use as therapeutics. 12,13 Another most important task is to HLA type UCB and allow for listing on a registry for rapid search and acquisition. 14 At present there are at least 142 public (three in India) and 25 private (seven in India) UCB banks worldwide. 12 Public banks are typically not-for-profit with their primary purpose being creation of an inventory of UCB units for unrelated use. UCB is donated to the bank, and the units are made available to suitably matched recipients regionally, nationally or internationally. Making samples from the public cord blood bank available to the masses would mean performing a six-part HLA typing on all the samples apart from the genetic screen for inborn errors. 15 This type of program in general is funded in part or entirely by public funds. The alternative approach involves for-profit companies which encourage parents to bank their child s UCB for their own (autologous) or a family member s (related, allogeneic) use should a need arise. For a fee, the UCB is processed and stored as a form of biological insurance. 16 STEM CELL BANKING IN INDIA With India s booming birth rate of 26 million births per year 17 and genetic diversity, the country would be poised to be the largest collector of UCB in the world. However, to set up a stem cell bank it requires proper networking among hospitals for supply of cord blood. The major problem faced in India is collection of UCB due to high cost and comparatively less functional public banks. In addition, considering a large population with deliveries in public hospital due to low cost, UCB storage in India needs increased public-private partnership model where UCB can be stored by affordable and non-affordable people as well. Reliance Life Sciences (RLS) established the first public bank ReliCord in 2002 and later extended the cord blood stem cell banking services to families. This cord blood repository has been accorded a license by Food and Drug Administration (FDA), Government of India and also has been inspected and accredited by AABB. It was the first cord blood repository to be set up in India and South Asia. The other public cord blood banks with nominal presence are Jeevan Stem Cell Blood Bank and StemCyte which are not-for-profit stem cell bank. ReliCord, Jeevan Cord and StemCyte collectively have 5,000 units of UCB. Similarly, seven private banks have been established to date in India. These are LifeCell with maximum inventory of 19,000 followed by Cryobanks having 17,000 plus samples and about 4,500 between Cryosave, Cord Life, Baby Cell, Stem One and International Stem Cell Service (ISSL) (personal communication from Dr Phagun Shah, Medical Advisor, Cryobank, India). Four of these are certified by ISO whereas LifeCell is also accredited by AABB. Most of these are affiliated with or are subsidiaries of international companies. Wherein Cryobanks International India plans to increase to 250 plus towns, LifeCell already has 40 collection centers across Asia. Narayana Health City, Bengaluru also recently came up with a public stem cell bank and Sri Ramachandra Deemed Medical University and Medical Center (SRMC), Chennai, in association with LifeCell has formed the therapy center TRICell. 16 The investments from the cord blood banks in India are mainly focused on the facility building, technology development fees and its day-to-day operations. Some of these companies have partners with experience in pharma industry. These companies have established a sale force wherein trained medical representatives visit the prospective client s home and explain the concept, collection and processing, and provide confidence on the storage facilities and even get in touch with the obstetrician, gynecologist on regular basis and get pregnant patient population from them. This will increase the customer base significantly as this opportunity is not restricted to expectant parents alone. Stem cell banking companies are making use of ready customer-base by tying up with hospitals, medical institutes, research institutions and biotechnology companies and stem cell therapy centers to aid in stem cell research as well as to enable this therapy within India. Another phase in stem cell banking is about to begin with companies launching new banking services (like collection of stem cells from menstrual blood, cord tissue and adipose tissue). UMBILICAL CORD BLOOD TRANSPLANTATION IN INDIA Most UCB banks in India have been opened in the last few years, and UCB transplantation is in its infancy, very few reports are available for application to acquire and constitutional hematological disorders and none for metabolic disorders. Till date approximately 32 patients have been transplanted using related or unrelated UCB. Of these 2 patients of relapsed leukemia were transplanted using mismatched sibling cord (UCB processed at LifeCell and Cryobank) and one died of

5 CHAPTER 170: Potential of Stem Cell Banking in India 1097 disease relapse and other of sepsis. One child was transplanted using fresh fully matched cord and the child is well 12 years on and did not go through any cord bank. In 15 patients mainly for relapsed leukemia and aplastic anemia, unrelated cord blood was used with transplant related mortality (TRM) of 55% at Apollo Hospitals, Chennai. While one patient of leukemia transplanted at Gujarat Cancer and Research Institute (GCRI), Ahmedabad, expired due to disease related mortality after transplantation. The high mortality rate appears to be due to selection of high risk cases under this group (personal communication with Dr Revathi Raj, Chennai, and Dr Sandip Shah, Ahmedabad). To date, around thirteen cases of thalassemia have been treated using UCB transplantation. Of these, six cases were transplanted using fully matched sibling UCB at Apollo Hospitals, Chennai. UCB units were obtained from LifeCell and cord bank. Thalassemia free survival was 83% and all patients had additional bone marrow from siblings as there was inadequate cell dose in cord blood (personal communication with Dr Revathi Raj, Chennai). Similarly, seven unrelated UCB units were utilized to treat thalassemia cases at Gujarat Cancer Research Institute (GCRI), Ahmedabad. The unrelated UCB units were procured from ReliCord and StemCyte UCB banks. TRM was 0% at both the centers. At GCRI, Ahmedabad, two thalassemia patients had disease free survival after 2 years and 1 year of transplantation, and one remained hospitalized post transplantation. Failure of engraftment was observed in four cases which is likely to be due to low number of total nucleated cell ( ) used in transplantation (personal communication from Dr Sandip Shah, Ahmedabad). Considering large number of thalassemia patients born in the country, these transplantations are comparatively very less mainly because of cost prohibition, lack of sufficient UCB depository and because public UCB banks are in early stage of development. In the coming years with an increased transplantation using UCB as a source of HSCs, more experience will undoubtedly be gained. 16,18 REGULATORY ENVIRONMENT IN INDIA AND OTHER COUNTRIES At present, the role that any government should play in UCB banking remains unclear. However, in developed and developing countries with a universally accessible healthcare system, public policymakers will soon be confronted with the difficult task of deliberating the merits and economics of establishing a national network of public UCB banks, including the value of private banking of UCB for autologous/family use. A policy framework may be necessary to guide this decision-making and to address the socioethical and legal issues surrounding UCB banking and uses. The guidelines from the Indian Council of Medical Research (ICMR) and Department of Biotechnology (DBT) are available to assist with stem cell research and UCB issues. 19 Additionally, the aforementioned standards (AABB, FACT/NetCord) could facilitate the effort to establish public UCB banks throughout India. Roughly 0.25% of the global shares of UCB transplants are done in India, and only three ICMR licensed UCB banks are operational in the country. 18,20 The field of UCB stem cell therapy is still gaining experience in India, and there are many regulatory and policy issues pertaining to the allogeneic transplantation for inherited disorders and transmissible infectious diseases that are yet to be addressed in addition to the draft guidelines by ICMR and DBT. There are unique ethical issues related to private UCB banking, and policymakers cannot chart the future of UCB banking in the country without taking into account the existence of private banks and their potential role in meeting future clinical needs, as well as their contribution to research in this domain. 16 India has great potential for UCB banking due to a high birth rate and genetic diversity. Nearly 70% of patients of Indian origin who require bone marrow transplantation do not find a match within their own family. Hence, unrelated UCB is a widely accepted source of progenitors for HSC transplantation. However, to date the total number of UCB transplants performed in India has been very low mainly due to high cost and limited number of UCB units available against the estimated requirement of 30,000 units. Moreover, in India, private UCB banking dominates and limits general public access to promising therapies. But with the existence of three public UCB banks, these figures are likely to improve in the coming years. This will offer a diverse source of high quality grafts for patients of Indian origin worldwide. Private banks will also continue to grow in India, as many families opt to store UCB in private banks with possible advantages in degenerative disorders in the future. To meet the future transplantation needs of the country, full participation and substantial investment by the government are necessary. Establishing a foundation, including infrastructure (facilities, technical and quality assurance expertise, etc.) will support a UCB program which will be representative for all regions of the country. 16 While standards appropriately cover, UCB banking guidelines regarding other issues including those with ethical implications (e.g. patient access, clinical applications) are lacking in particular for autologous UCB transplantation. Further, worldwide, clinical trials for a variety of diseases are ongoing despite inadequate pre-clinical studies and regulatory/safety oversight. However, the clinical research environment in India is currently undergoing a tremendous flux, with regulators coming under severe criticism from the press, public and the elected government. 21 There are new ICMR-DBT draft guidelines on stem cell research, and the Central Drugs Standard Control Organization (CDSCO) draft on compensation toward injury due to participation in clinical research that are responses to several questions that we face today. 22,23 If these guidelines are to have lasting credibility then they should be implemented. These stringent guidelines for stem cell research and therapy are yet to be legislated. The Union Health Ministry is planning a law to regulate this sector. The guidelines have to become law in a strict sense to attract global attention. WHAT IS THE GLOBAL AND INDIAN SCENARIO OF STEM CELL THERAPY? In the still emerging scenario of banking guidelines, a few FDA approved stem cell products are making into the clinics in various parts of the world. Osiris Therapeutics recently announced the approval of its product Prochymal by Canadian regulators to treat children suffering from acute GVHD, a potentially deadly complication of allogeneic bone marrow transplantation. Osiris also got similar approval in New Zealand for Prochymal. Another product by Osiris is Osteocel an allograft containing MSCs and osteoprogenitors and sold to NuVasive, Inc. in In Korea, Pharmicell has successfully developed Hearticellgram-AMI

6 1098 SECTION 21: Stem Cell Therapy autologous product and received approval from the Korea Federal Drug Agency (KFDA) in July 1, Hearticellgram-AMI uses autologous stem cells and is a personalized stem cell therapy product which overcomes immune rejection. Another Korean company, Medipost got approval for their product Cartistem in January 2012 from the Korean FDA for the treatment of OA. In India, patient s treatment through stem cell therapy has already paved its way. LV Prasad Eye Institute (LVPEI) has treated the largest number of patients (780) in the world for corneal blindness using cultured limbal stem cell therapy since the institute started the procedure in The therapy is used to restore vision in cases of corneal damage due to burns or chemical injury. Some hospitals and stem cell companies are offering stem cell therapy for spinal cord injury, Parkinson s disease, stroke and cardiovascular indications. Stempeutics Research, a group company of Manipal Education and Medical Group, is the only company in the country which has developed Stempeucel, an investigational medicinal product which is undergoing the last stage of phase 2 clinical trial for the indication of critical limb ischemia (CLI), osteoarthritis (OA) and liver cirrhosis (LC) and is expected to enter phase 3 trial by early The company plans to launch Stempeucel in the Indian market by mid CONCLUSION With everyday advancements in stem cell technology from the research and clinical perspective, stem cells do promise a healthy future for the coming generations in India. Currently, UCB and cord-tissue banking are more popular. For optimal utilization of these facilities, it is important to create concept awareness. At present, lack of awareness among the common people about the huge potential to be gained from the storage of cord blood stem cells and highly technical nature of the process is the key reason for a small customer base in the country. It is still considered an ultimate preventive healthcare luxury due to high-cost barriers. Increased awareness levels among the masses about the concept and a strong legalized and less commercialized environment can work positively toward making stem cell banking an integral part of Indian healthcare. REFERENCES 1. Cohen Y, Nagler A. Umbilical cord blood transplantation how, when and for whom? Blood Rev. 2004:18: Martin PL, Carter SL, Kernan NA, et al. Results of the cord blood transplantation study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases. Biol Blood Marrow Transplant. 2006:12: Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004:351: Sharma A. Stem cell research in India: emerging scenario and policy concerns. Asian Biotechnology and Development Review. 2006:8: Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi s anemia by means of umbilicalcord blood from HLA-identical sibling. N Engl J Med. 1989;321: Cohen Y, Nagler A. Hematopoietic stem-cell transplantation using umbilical cord blood. Leuk Lymphoma. 2003;44: American Academy of Pediatrics Section on Hematology/Oncology, American Academy of Pediatrics Section on Allergy/immunology, Lusin BH, et al. Cord blood banking for potential future transplantation. Pediatrics. 2007:119: Bensinger WI, Clift R, Martin P, et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood. 1996:88: McCullough J, McKenna D, Kadidlo D, et al. Issues in the quality of umbilical cord blood stem cells for transplantation. Transfusion. 2005;45: Standards for cellular therapy product services. Standards for Cellular Therapy Product Services, 2nd edition. Bethesda MD: American Association of Blood Banks; Net Cord Foundation for the Accreditation of Cellular Therapy. International Standards for Cord Blood Collection, Processing, Testing, Banking, Selection and Release, 3rd edition. Bethesda, MD: American Association of Blood Banks; [online] Available from Subcommittees/Cord_Blood_Working_Group/Cord_Blood_Banks_ Worldwide_ pdf. [Accessed June, 2014]. 13. Cord blood Registry. Why you should save cord blood for your family. [online] Available from banking_with_cbr/banking/diseases_treated.asp?fbid=blys_oaig4n. [Accessed June, 2014]. 14. Barker JN, Krepski TP, DeFor TE, et al. Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow. Biol Blood Marrow Transplant. 2002;8: National Marrow Donor Program. Where to donate cord blood. Minneapolis (MN): NMDP; [online] Available from marrow.org/help/donate_cord_blood_share_life/how_to_donate_ Cord_Blood/CB_Participating_Hospitals/nmdp_cord_blood_hospitals. pl. [Accessed June, 2014]. 16. McKenna D, Sheth J. Umbilical cord blood: current status and promise for the future. Indian J Med Res. 2011:134: Save the children. Child mortality in India. [online] Available from html. [Accessed June, 2014]. 18. Umbilical cordblood. [online] Available from parentsguidecordblood.org/content/usa/banklists/summary. shtml#india. [Accessed June, 2014]. 19. ICMR-DBT guidelines for stem cell research and therapy. (2006). [online] Available from [Accessed June, 2014]. 20. Umbilical cordblood. [online] Available from parentsguidecordblood.org/content/usa/banklists/regulations. shtml?navid=31#india. [Accessed June, 2014]. 21. Department-related parliamentary Standing Committee on health and family welfare, 59th Report on the Functioning of the Central Drugs Standard Control Organization (CDSCO), Government of India. [online] Available from reports/englishcommittees/committee%20on%20health%20and%20 family%20welfare/59.pdf. [Accessed June, 2014]. 22. Center drugs standard control organization (2014). Draft guidelines on formula to determine the quantam of compensation in case of clinical trial related injury.[online] Available from: readdata/uploaded_for_website_1_final2014.pdf. 23. ICMR DBT guidelines for stem cell research. [online] Available from [Accessed June, 2014].

UMBILICAL CORD BANKING. (formerly Unistem Biosciences Pvt.Ltd.)

UMBILICAL CORD BANKING. (formerly Unistem Biosciences Pvt.Ltd.) UMBILICAL CORD BANKING (formerly Unistem Biosciences Pvt.Ltd.) INITIATIVES OF CELLUGEN BIOTECH PVT.LTD. (formerly Unistem Biosciences Pvt.Ltd.) UMBILICAL CORD BANKING UMBILICAL CORD STEM CELL THERAPY Stem

More information

What we will discuss today

What we will discuss today Umbilical cord blood banking It s Utility? Dr. Nita Radhakrishnan Pediatric Hematology Oncology Unit, Sir Ganga Ram Hospital, New Delhi What we will discuss today What are stem cells? What are the sources

More information

4. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.

4. All cord blood banks should be subject to the same standards, regulations and accreditation requirements. WMDA Policy Statement on the Utility of Autologous or Family Cord Blood Unit Storage The WMDA Board adopted this policy on 25 th of May 2006. Policy updated _April 2011 The Cord Blood Working Group and

More information

STEM CELLS FROM THE UMBLICAL CORD BLOOD AND UMBLICAL CORD TISSUE

STEM CELLS FROM THE UMBLICAL CORD BLOOD AND UMBLICAL CORD TISSUE STEM CELLS FROM THE UMBLICAL CORD BLOOD AND UMBLICAL CORD TISSUE What are Stem Cells? Stem cells are the basic building blocks of all the cells, tissues and organs in the human body. The role of the stem

More information

5. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.

5. All cord blood banks should be subject to the same standards, regulations and accreditation requirements. WMDA Policy Statement for the Utility of Autologous or Family Cord Blood Unit Storage (This policy statement has been approved and adopted by the WMDA board on the 25 th of May 2006) The Cord Blood Registries

More information

Cord Blood Stem Cell Transplantation

Cord Blood Stem Cell Transplantation LEUKEMIA LYMPHOMA MYELOMA FACTS Cord Blood Stem Cell Transplantation No. 2 in a series providing the latest information on blood cancers Highlights Umbilical cord blood, like bone marrow and peripheral

More information

Placental/Umbilical Cord Blood as a Source of Stem Cells. Original Policy Date

Placental/Umbilical Cord Blood as a Source of Stem Cells. Original Policy Date MP 7.01.38 Placental/Umbilical Cord Blood as a Source of Stem Cells Medical Policy Section Surgery Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013

More information

UMBILICAL CORD BLOOD HARVESTING & STORAGE

UMBILICAL CORD BLOOD HARVESTING & STORAGE Protocol: TRP009 Effective Date: October 14, 2013 UMBILICAL CORD BLOOD HARVESTING & STORAGE Table of Contents Page COMMERCIAL, MEDICARE & MEDICAID COVERAGE RATIONALE... 1 BACKGROUND... 2 CLINICAL EVIDENCE...

More information

Not All Stem Cells are the Same

Not All Stem Cells are the Same Cord Blood Banking and Transplantation Jennifer Willert, M.D. Hematology/Oncology Blood and Marrow Transplant Rady Children s Hospital San Diego Clinical Professor UCSD Not All Stem Cells are the Same

More information

It s not something you want to think about, but it s something you want to prepare for.

It s not something you want to think about, but it s something you want to prepare for. It s not something you want to think about, but it s something you want to prepare for. StemCyte cord blood banking offers your family a new lifesaving treatment alternative Why Bank Take the once-in-alifetime

More information

CIGNA HEALTHCARE COVERAGE POSITION

CIGNA HEALTHCARE COVERAGE POSITION CIGNA HEALTHCARE COVERAGE POSITION Subject Umbilical Cord Blood Banking Table of Contents Coverage Position... 1 General Background... 1 Coding/Billing Information... 3 References... 3 Revised Date...

More information

UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE

UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE HIND AL HUMAIDAN, MD,FRCPA Director, Blood Bank (Donor & Transfusion Services) and Stem Cell Cord Blood Bank Consultant Hematopathologist INTRODUCTION

More information

Corporate Medical Policy Cord Blood as a Source of Stem Cells

Corporate Medical Policy Cord Blood as a Source of Stem Cells Corporate Medical Policy Cord Blood as a Source of Stem Cells File Name: Origination: Last CAP Review: Next CAP Review: Last Review cord_blood_as_a_source_of_stem_cells 2/2001 3/2015 3/2016 3/2015 Description

More information

CORD BLOOD BANKING FAQ

CORD BLOOD BANKING FAQ CORD BLOOD BANKING FAQ Cord Blood & Stem Cells Q: What is umbilical cord blood (UCB)? A: Bone marrow, peripheral blood and UCB constitute the three primary sources of stem cells. Cord blood, which, until

More information

SAVE A LIFE... BY GIVING LIFE!

SAVE A LIFE... BY GIVING LIFE! SAVE A LIFE... BY GIVING LIFE! FOLLOW US ON: HÉMA-QUÉBEC PUBLIC CORD BLOOD BANK www.hema-quebec.qc.ca Scan this code with your smart phone to access the page Register to the Public Cord Blood Bank on the

More information

Corporate Medical Policy Cord Blood as a Source of Stem Cells

Corporate Medical Policy Cord Blood as a Source of Stem Cells Corporate Medical Policy Cord Blood as a Source of Stem Cells File Name: Origination: Last CAP Review: Next CAP Review: Last Review cord_blood_as_a_source_of_stem_cells 2/2001 3/2015 3/2016 3/2015 Description

More information

Cord Blood Bank Business Plan

Cord Blood Bank Business Plan Cord Blood Bank Business Plan A sample of how to create a new program Produced by the AABB subsection: Cellular Therapy Business Management with major contributions by Nicole Omer TABLE OF CONTENTS Page

More information

Placental and Umbilical Cord Blood as a Source of Stem Cells

Placental and Umbilical Cord Blood as a Source of Stem Cells Placental and Umbilical Cord Blood as a Source of Stem Cells Policy Number: 7.01.50 Last Review: 12/2015 Origination: 12/2001 Next Review: 12/2016 Policy Blue Cross and Blue Shield of Kansas City (Blue

More information

CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION

CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION Chapter 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION 1.1 OVERVIEW OF THE CORD BLOOD TRANSPLANTATION STUDY Bone marrow transplantation

More information

UMBILICAL CORD BLOOD STATISTICS

UMBILICAL CORD BLOOD STATISTICS UMBILICAL CORD BLOOD STATISTICS INTRODUCTION Stem cells are the next frontier in medicine. Stem cells are thought to have great therapeutic and biotechnological potential. This will not only to replace

More information

Placental and Umbilical Cord Blood as a Source of Stem Cells

Placental and Umbilical Cord Blood as a Source of Stem Cells Placental and Umbilical Cord Blood as a Source of Stem Cells Policy Number: 7.01.50 Last Review: 12/2013 Origination: 12/2001 Next Review: 12/2014 Policy Blue Cross and Blue Shield of Kansas City (Blue

More information

House Resolution No. 37

House Resolution No. 37 california legislature regular session House Resolution No. Introduced by Assembly Member Hill August, House Resolution No. Relative to umbilical cord blood banking. WHEREAS, Since the first umbilical

More information

Placental and Umbilical Cord Blood as a Source of Stem Cells

Placental and Umbilical Cord Blood as a Source of Stem Cells Placental and Umbilical Cord Blood as a Source of Stem Cells Policy Number: 7.01.50 Last Review: 12/2014 Origination: 12/2001 Next Review: 12/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue

More information

Cigna Medical Coverage Policy

Cigna Medical Coverage Policy Cigna Medical Coverage Policy Subject Umbilical Cord Blood Banking Table of Contents Coverage Policy... 1 General Background... 1 Coding/Billing Information... 3 References... 4 Effective Date... 6/15/2014

More information

Stem Cell Background Paper

Stem Cell Background Paper Stem Cell Background Paper Introduction...2 Stem Cell Basics...3 Stem Cell Process Flow...9 Comparison of Blood, Stem Cells, Tissues and Organs Processes...10 Responsibilities for the Blood, Stem Cells,

More information

Top Ten Things to Know About Stem Cell Treatments

Top Ten Things to Know About Stem Cell Treatments Top Ten Things to Know About Stem Cell Treatments Many clinics that are offering stem cell treatments make claims about what stem cells can and cannot do that are not supported by our understanding of

More information

Saving your baby s s cord blood: Is this good insurance?

Saving your baby s s cord blood: Is this good insurance? Saving your baby s s cord blood: Is this good insurance? 32 th SEMINAR ON PERINATAL MEDICINE CONTROVERSIES IN PERINATAL MEDICINE: EVIDENCE FOR CURRENT PRACTICE Sante Fe, New Mexico Mervin C. Yoder, MD

More information

UMBILICAL CORD BLOOD, STEM CELL BANKING

UMBILICAL CORD BLOOD, STEM CELL BANKING UMBILICAL CORD BLOOD, STEM CELL BANKING Dr.Sharad Jain MD Blood Transfusion officer, & I/C Transfusion Medicine NSCB Medical College. Jabalpur.MP. Introduction: Every parent during childbirth DREAMS the

More information

cord blood saves lives...

cord blood saves lives... cord blood saves lives... ...by providing a rich source of blood stem cells that can be used to treat over 80 different diseases including leukemia, lymphoma, thalassemia, Tay-Sachs and sickle cell anemia.

More information

Name of Policy: Placental/Umbilical Cord Blood as a Source of Stem Cells

Name of Policy: Placental/Umbilical Cord Blood as a Source of Stem Cells Name of Policy: Placental/Umbilical Cord Blood as a Source of Stem Cells Policy #: 439 Latest Review Date: September 2014 Category: Medical Policy Grade: A Background/Definitions: As a general rule, benefits

More information

A Cure for Sickle Cell Anemia and Thalassemia

A Cure for Sickle Cell Anemia and Thalassemia IV Simpósio Internacional de Hemoglobinopatias A Cure for Sickle Cell Anemia and Thalassemia Bertram Lubin, MD and Mark Walters, MD 4 September 2007 Topics to be covered Cord blood: Importance and biology

More information

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY Original Issue Date (Created): 4/1/2011 Most Recent Review Date (Revised): 3/24/2015 Effective Date: 6/1/2015 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER

More information

Statement of Joanne Kurtzberg, M.D.

Statement of Joanne Kurtzberg, M.D. Statement of Joanne Kurtzberg, M.D. President of the Cord Blood Association Jerome Harris Distinguished Professor of Pediatrics and Pathology Chief Scientific Officer and Medical Director, Robertson Clinical

More information

Cord Cor Blood Banking Scott N. Furlan, MD Ellen S. Plummer, Plummer MD

Cord Cor Blood Banking Scott N. Furlan, MD Ellen S. Plummer, Plummer MD Cord Blood Banking Scott N. Furlan, MD Ellen S.Plummer, MD Overview Background Biology of Stem Cell Transplant Opportunities i at Parkland Logistics of Banking Potential Barriers Indications for HCT Cancer

More information

Do you have anything to add? If so, I d love to hear from you! Jessica Robinson Conference Manager Life Sciences @jessbiopharma

Do you have anything to add? If so, I d love to hear from you! Jessica Robinson Conference Manager Life Sciences @jessbiopharma 1 Who is the most influential figure in cord blood around the world? What is the biggest challenge to overcome in the use of cord blood as a source of stem cells? We asked 10 leading experts in the cord

More information

Cord Blood Banking A new horizon

Cord Blood Banking A new horizon Cord Blood Banking A new horizon Dr. Sushma Sharma Professor Obst. & Gyn., MIMER Medical College, Talegaon Dabhade, Pune. Abstract : Background : Umbilical cord blood is a potential vast source of primitive

More information

Phone: +44 20 8123 2220 Fax: +44 207 900 3970 office@marketpublishers.com http://marketpublishers.com

Phone: +44 20 8123 2220 Fax: +44 207 900 3970 office@marketpublishers.com http://marketpublishers.com Global Stem Cell Umbilical Cord Blood (UCB) Market (Storage Service, Therapeutics, Application, Geography) - Size, Share, Global Trends, Analysis, Opportunities, Growth, Intelligence and Forecast, 2012-2020

More information

Donation of Umbilical Cord Blood. A precious life offer. for everyone!

Donation of Umbilical Cord Blood. A precious life offer. for everyone! Donation of Umbilical Cord Blood A precious life offer for everyone! Donation of Umbilical Cord Blood A precious life offer for everyone! Page 3 Hellenic Cord Blood Bank Page 4 Haematopoietic Progenitor

More information

guides BIOLOGY OF AGING STEM CELLS An introduction to aging science brought to you by the American Federation for Aging Research

guides BIOLOGY OF AGING STEM CELLS An introduction to aging science brought to you by the American Federation for Aging Research infoaging guides BIOLOGY OF AGING STEM CELLS An introduction to aging science brought to you by the American Federation for Aging Research WHAT ARE STEM CELLS? Stem cells are cells that, in cell cultures

More information

Transplantation of cord blood stem cells from related or unrelated donors is considered investigational in all other situations.

Transplantation of cord blood stem cells from related or unrelated donors is considered investigational in all other situations. MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Placental and Umbilical Cord Blood as a Source of Stem Cells

More information

Umbilical Cord Blood Stem Cells Current Status & Future Potential

Umbilical Cord Blood Stem Cells Current Status & Future Potential Umbilical Cord Blood Stem Cells Current Status & Future Potential Natasha Ali Assistant Professor Haematology Department of Pathology & Laboratory Medicine/Oncology The Aga Khan University Email: natasha.ali@aku.edu

More information

Section: Transplant Last Reviewed Date: January 2015. Policy No: 45.16 Effective Date: April 1, 2015

Section: Transplant Last Reviewed Date: January 2015. Policy No: 45.16 Effective Date: April 1, 2015 Medical Policy Manual Topic: Placental and Umbilical Cord Blood as a Source of Stem Cells Date of Origin: December 2009 Section: Transplant Last Reviewed Date: January 2015 Policy No: 45.16 Effective Date:

More information

PT CordLife Indonesia Premium Cordblood Bank. PT CordLife Indonesia Premium Cordblood Bank

PT CordLife Indonesia Premium Cordblood Bank. PT CordLife Indonesia Premium Cordblood Bank Cordblood Stem Cells and The Role of Cordblood Bank in Supporting Stem Cells Research Presentation Overview Company profile Haematopoietic stem cells in cordblood What we can do to help 1 2 PT CordLife

More information

Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape

Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape GENReports: Market & Tech Analysis Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director SELECTBIO US enal@selectbio.us

More information

DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT

DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT www.narayanahealth.org DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT About Narayana Health City Narayana Health, one of India's largest and the world's most economical healthcare service providers

More information

your complete stem cell bank

your complete stem cell bank your complete stem cell bank HYDERABAD - 88985 000 888, WARANGAL - 8297 256 777 VISAKHAPATNAM - 7799 990 774 VIJAYAWADA AND GUNTUR - 7799 990 771 NELLORE - 7799 990 772, KADAPA - 8297 256 700 RAJAHMUNDRY

More information

Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood

Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood [Track 2: What Is a Transplant?] Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood can be an effective treatment for people with blood cancers such as leukemia,

More information

STEM CELLS : A THERAPEUTIC REVOLUTION JACQUES KADOCH ROBERT HEMMINGS MARINELA MANDRA

STEM CELLS : A THERAPEUTIC REVOLUTION JACQUES KADOCH ROBERT HEMMINGS MARINELA MANDRA STEM CELLS : A THERAPEUTIC REVOLUTION JACQUES KADOCH ROBERT HEMMINGS MARINELA MANDRA OVO CLINIC I 8000 BLVD DECARIE, MONTREAL QC H4P 2S4 I 514.798.2000 I OVOCLINIC.COM 2 a therapeutic revolution As the

More information

The Facts about Cord Blood

The Facts about Cord Blood The Facts about Cord Blood Dear Future Mom and/or Dad, All of us at CorCell would like to give you a big CONGRATULATIONS on your new baby! Now that you are expecting, you have probably heard about saving

More information

Jamie Peregrine, MD, PGY-4 KU-Wichita, OB/GYN Wesley Medical Center

Jamie Peregrine, MD, PGY-4 KU-Wichita, OB/GYN Wesley Medical Center Jamie Peregrine, MD, PGY-4 KU-Wichita, OB/GYN Wesley Medical Center Uses for umbilical cord stem cells Describe the indications and uses for umbilical cord stem cells. Counsel patients on the advantages

More information

Fetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant. Recipients

Fetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant. Recipients Fetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant Recipients Filippo Milano, 1 J. Lee Nelson, 1, 2 Colleen Delaney 1,3 1 Clinical Research Division, Fred Hutchinson Cancer Research

More information

A Public Cord Blood Bank for South Africa? i

A Public Cord Blood Bank for South Africa? i No. 42/2007 A Public Cord Blood Bank for South Africa? i By Dr Robert Crookes MBChB (Wits), Dip. Internal Medicine (American Board of Internal Medicine, USA) Transfusion Medicine Consultant. South African

More information

In a number of genetic, hematologic, and oncologic

In a number of genetic, hematologic, and oncologic AMERICAN ACADEMY OF PEDIATRICS Cord Blood Banking for Potential Future Transplantation: Subject Review ABSTRACT. In recent years, umbilical cord blood, which contains a large number of hematopoietic stem

More information

Umbilical cord blood: Current status & promise for the future

Umbilical cord blood: Current status & promise for the future Review Article Indian J Med Res 134, September 2011, pp 261-269 Umbilical cord blood: Current status & promise for the future David McKenna & Jayesh Sheth * Molecular & Cellular Therapeutics, University

More information

Umbilical Cord Blood Stem Cell Research: The Proof is in the Cord

Umbilical Cord Blood Stem Cell Research: The Proof is in the Cord Cauley O. Gieb Advanced Health Law HLP Article Umbilical Cord Blood Stem Cell Research: The Proof is in the Cord Today advances in science seem to gain the most recognition and support when the subject

More information

Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points

Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Bone Marrow Transplantation

More information

A Gift for life. HTA Licence No. 22653

A Gift for life. HTA Licence No. 22653 A Gift for life HTA Licence No. 22653 2 3 the best possible gift for your new born child. 4 6 8 9 10 12 14 16 19 what is cord blood current treatments services contents properties for treatment process

More information

THE NEW ZEALAND MEDICAL JOURNAL

THE NEW ZEALAND MEDICAL JOURNAL THE NEW ZEALAND MEDICAL JOURNAL Vol 118 No 1208 ISSN 1175 8716 Private umbilical cord blood banking: a biological insurance of dubious future benefit! Michael Sullivan, Peter Browett, Nigel Patton In its

More information

Published:October2011. Thestudyreviews,analyzesandprojects theglobalmarketforcordbloodstem Cels fortheperiod2006-2015. 2011alrightsreserved

Published:October2011. Thestudyreviews,analyzesandprojects theglobalmarketforcordbloodstem Cels fortheperiod2006-2015. 2011alrightsreserved Published:October2011 Thestudyreviews,analyzesandprojects theglobalmarketforcordbloodstem Cels fortheperiod2006-2015 2011alrightsreserved PRODUCT SEGMENTATION Cord blood stem cells are those adult stem

More information

H. R. 2107 IN THE HOUSE OF REPRESENTATIVES

H. R. 2107 IN THE HOUSE OF REPRESENTATIVES I 1TH CONGRESS 1ST SESSION H. R. 2107 To direct the Secretary of Health and Human Services to conduct a public education campaign on umbilical cord blood stem cells, and for other purposes. IN THE HOUSE

More information

Summary of Advisory Council on Blood Stem Cell Transplantation: Recommendations and Status

Summary of Advisory Council on Blood Stem Cell Transplantation: Recommendations and Status of Advisory Council on Blood Stem Cell Transplantation: Recommendations and Shelley Grant Branch Chief, Blood Stem Cell Transplantation Program September 11, 2015 Overview December 20, 2005 - HRSA began

More information

Informed Consent in Umbilical Cord Blood Collection, Storage and Donation: A Bloody Mess

Informed Consent in Umbilical Cord Blood Collection, Storage and Donation: A Bloody Mess Informed Consent in Umbilical Cord Blood Collection, Storage and Donation: A Bloody Mess Susan P. Raine, J.D., M.D., L.L.M. Candidate Over the past decade, umbilical cord blood has gone from being discarded

More information

Blood-Forming Stem Cell Transplants

Blood-Forming Stem Cell Transplants Blood-Forming Stem Cell Transplants What are bone marrow and hematopoietic stem cells? Bone marrow is the soft, sponge-like material found inside bones. It contains immature cells known as hematopoietic

More information

Stem Cell Quick Guide: Stem Cell Basics

Stem Cell Quick Guide: Stem Cell Basics Stem Cell Quick Guide: Stem Cell Basics What is a Stem Cell? Stem cells are the starting point from which the rest of the body grows. The adult human body is made up of hundreds of millions of different

More information

Hematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine

Hematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells

More information

Pros and Cons of Stem Cell Sources and their availability in Africa. Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa

Pros and Cons of Stem Cell Sources and their availability in Africa. Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa Pros and Cons of Stem Cell Sources and their availability in Africa Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa Introduction The ability to perform a haematopoietic stem

More information

U.S. Department of Health and Human Services. Are Distributed to Cord Blood Banks Participating In the National Cord Blood Inventory.

U.S. Department of Health and Human Services. Are Distributed to Cord Blood Banks Participating In the National Cord Blood Inventory. U.S. Department of Health and Human Services Interim DRAFT: Report DO to NOT Congress CIRCULATE on How Federal Funds Are Distributed to Cord Blood Banks Participating In the National Cord Blood Inventory

More information

Media coverage, marketing,

Media coverage, marketing, : A Guide for Primary Care Physicians PAUL L. MARTIN, MD, PhD, and JOANNE KURTZBERG, MD, Duke University Medical Center, Durham, North Carolina BRETT HESSE, MD, St. Vincent Hospital, Indianapolis, Indiana

More information

Vita 34 Parents Guide to umbilical Cord Blood Banking. secure first-class innovative

Vita 34 Parents Guide to umbilical Cord Blood Banking. secure first-class innovative Vita 34 Parents Guide to umbilical Cord Blood Banking secure first-class innovative Contents INTRODUCTION 3 THERAPEUTIC USES OF STEM CELLS 4 STEM CELLS IN CANCER TREATMENT STEM CELLS IN THE TREATMENT OF

More information

CONSENT FORM. Cord Blood Banking for Transplantation

CONSENT FORM. Cord Blood Banking for Transplantation Cord Blood Program Northwest Tissue Center/Puget Sound Blood Center 921 Terry Avenue Seattle, WA 98104 (206) 292-1896 Swedish Medical Center 747 Broadway Seattle, WA 98122 (206) 386-6000 CONSENT FORM Cord

More information

Zutphen, 15 May 2013 Arnoud van Tulder Chief Executive Officer

Zutphen, 15 May 2013 Arnoud van Tulder Chief Executive Officer Zutphen, 15 May 2013 Arnoud van Tulder Chief Executive Officer 1 Non-recurring events 2012 Non-recurring costs in 2012 of 16.2 million: - Non-cash impairment of goodwill and other assets: 15.1 million

More information

Umbilical Cord Blood Transplantation

Umbilical Cord Blood Transplantation Umbilical Cord Blood Transplantation V Rocha MD, PhD Hopital Saint Louis, Paris University 7 CIBMTR Milwaukee Umbilical Cord blood transplantation Background History Clinical results in children and adults

More information

INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002

INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002 INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002 COVERAGE: SPECIAL COMMENT ON POLICY REVIEW: Due to the complexity of the Peripheral and Bone Marrow Stem Cell Transplantation

More information

ASSEMBLY, No. 2591 STATE OF NEW JERSEY. 212th LEGISLATURE INTRODUCED FEBRUARY 23, 2006

ASSEMBLY, No. 2591 STATE OF NEW JERSEY. 212th LEGISLATURE INTRODUCED FEBRUARY 23, 2006 ASSEMBLY, No. STATE OF NEW JERSEY th LEGISLATURE INTRODUCED FEBRUARY, 00 Sponsored by: Assemblywoman CHARLOTTE VANDERVALK District (Bergen) SYNOPSIS Requires hospitals to provide information to pregnant

More information

Public Cord Blood Tissue Bank Committee on Health Care Services and Representative Peaden

Public Cord Blood Tissue Bank Committee on Health Care Services and Representative Peaden HOUSE OF REPRESENTATIVES COMMITTEE ON HEALTH CARE SERVICES ANALYSIS BILL #: HB 2337 (PCB HCS 00-07) RELATING TO: SPONSOR(S): TIED BILL(S): Public Cord Blood Tissue Bank Committee on Health Care Services

More information

UMBILICAL CORD BLOOD BANKING. A guide for parents

UMBILICAL CORD BLOOD BANKING. A guide for parents UMBILICAL CORD BLOOD BANKING A guide for parents This guide has been elaborated by the Council of Europe European Committee on Organ Transplantation (CD-P-TO). For more information, please visit https://go.edqm.eu/transplantation.

More information

Canadian Blood Services National Public Cord Blood Bank Give Life Twice Transfusion Medicine Residents

Canadian Blood Services National Public Cord Blood Bank Give Life Twice Transfusion Medicine Residents Canadian Blood Services National Public Cord Blood Bank Give Life Twice Transfusion Medicine Residents Eileen Quinlan Collection Supervisor, Brampton (GTA) 2015-11-10 History One Match Stem Cell and Marrow

More information

Cord Blood: Research Progress and Future Promise

Cord Blood: Research Progress and Future Promise Cord Blood: Research Progress and Future Promise By Al Staropoli, AABB Contributing Writer Sue Fister found out she had leukemia when she was 50 years old. Doctors suggested a bone marrow transplant as

More information

UMBILICAL CORD BLOOD BANKING A guide for parents

UMBILICAL CORD BLOOD BANKING A guide for parents UMBILICAL CORD BLOOD BANKING A guide for parents 2 nd EDITION INTRODUCTION The cells contained in the umbilical cord blood have therapeutic value for the treatment of blood disorders and immune diseases.

More information

Selecting an appropriately matched donor for hematopoietic

Selecting an appropriately matched donor for hematopoietic Transplant Outcomes in Acute Leukemia (I) Mary Eapen a and John E. Wagner b Umbilical cord blood (UCB) has gradually emerged over the last decade as an alternative source of hematopoietic cells for transplantation

More information

The donor search: the best donor or cord blood unit

The donor search: the best donor or cord blood unit The donor search: the best donor or cord blood unit Dr Bronwen Shaw Consultant in haematopoietic cell transplantation Royal Marsden Hospital /Anthony Nolan Overview Where do we find donors/units for transplantation

More information

Discover the Possibilities Born With Your Baby

Discover the Possibilities Born With Your Baby Discover the Possibilities Born With Your Baby Your Simple Guide to Saving Cord Blood The Power and Promise The lifesaving power of cord blood and regenerative healing potential of cord blood and cord

More information

A Biological Insurance Protecting Your Future

A Biological Insurance Protecting Your Future A Biological Insurance Protecting Your Future Dear Parent(s), At this time we would like to thank you for your interest in LifeSource Cryobank, LLC. You, like many other expectant parents, are choosing

More information

A fact sheet UNRELATED BONE MARROW AND CORD BLOOD STEM CELL TRANSPLANTS

A fact sheet UNRELATED BONE MARROW AND CORD BLOOD STEM CELL TRANSPLANTS A fact sheet UNRELATED BONE MARROW AND CORD BLOOD STEM CELL TRANSPLANTS Each year, thousands of patients are diagnosed with diseases treatable by a blood stem cell transplant. These blood stem cells can

More information

Cord blood for the treatment of acute lymphoblastic leukemia in young children

Cord blood for the treatment of acute lymphoblastic leukemia in young children Cord blood for the treatment of acute lymphoblastic leukemia in young children By Caitlin McGreevy Kiara Paramjothy Pass with Merit RESEARCH PAPER BASED ON PATHOLOGY LECTURES AT MEDLINK 2011 1 Abstract:

More information

CORD BLOOD TRANSPLANTATION STUDY EXPANDED ACCESS PROTOCOL APPENDIX A SAMPLE CONSENT FORM

CORD BLOOD TRANSPLANTATION STUDY EXPANDED ACCESS PROTOCOL APPENDIX A SAMPLE CONSENT FORM APPENDIX A SAMPLE CONSENT FORM CORD BLOOD TRANSPLANTATION (COBLT) STUDY SAMPLE CONSENT FORM FOR THE EXPANDED ACCESS PROTOCOL You (your child) are being asked to take part in a clinical research study.

More information

Demystifying Stem Cells. Brent Bost M.D., CPA, MBA, FACOG

Demystifying Stem Cells. Brent Bost M.D., CPA, MBA, FACOG Demystifying Stem Cells Brent Bost M.D., CPA, MBA, FACOG Disclaimers Author currently serves on Board of Directors of CordTrack Most applications discussed today are not currently FDA approved and are,

More information

EUROCORD. in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases

EUROCORD. in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases ! 21%! EUROCORD 6756 cord blood transplantations performed from 1988 to March 2010 in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases * missing center

More information

International NetCord Foundation Executive Committee Conference Call Minutes May 23, 2007

International NetCord Foundation Executive Committee Conference Call Minutes May 23, 2007 International NetCord Foundation Executive Committee Conference Call Minutes Committee Members: Board Members: Staff: President Joan Garcia and Drs. Yves Beguin and Elizabeth Shpall Drs. Cristina Navarrete

More information

umbilical cord blood banking A guide for parents

umbilical cord blood banking A guide for parents umbilical cord blood banking A guide for parents 2 nd Edition 2016 This guide has been elaborated by the Council of Europe European Committee on Organ Transplantation (CD-P-TO). For more information, please

More information

What is a Stem Cell Transplantation?

What is a Stem Cell Transplantation? What is a Stem Cell Transplantation? Guest Expert: Stuart, MD Associate Professor, Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Drs. Ed and Ken. I am

More information

STEM CELL FACTS. The ISSCR is an independent, nonproft organization providing a global forum for stem cell research and regenerative medicine.

STEM CELL FACTS. The ISSCR is an independent, nonproft organization providing a global forum for stem cell research and regenerative medicine. STEM CELL FACTS The ISSCR is an independent, nonproft organization providing a global forum for stem cell research and regenerative medicine. WHAT ARE STEM CELLS? Stem cells are the foundation cells for

More information

STEM CELL THERAPEUTIC AND RESEARCH ACT OF 2005

STEM CELL THERAPEUTIC AND RESEARCH ACT OF 2005 STEM CELL THERAPEUTIC AND RESEARCH ACT OF 2005 VerDate 14-DEC-2004 06:53 Jan 05, 2006 Jkt 039139 PO 00000 Frm 00001 Fmt 6579 Sfmt 6579 E:\PUBLAW\PUBL129.109 APPS10 PsN: PUBL129 119 STAT. 2550 PUBLIC LAW

More information

Bone Marrow/Stem Cell Transplant

Bone Marrow/Stem Cell Transplant Blue Distinction Centers for Transplants Program Selection Criteria for 2010 Mid-Point Designations To qualify as a Blue Distinction Center for Transplants (), each facility must satisfy s quality based

More information

Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease

Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease 1 Produced by St. Jude Children s Research Hospital Departments of Hematology, Patient

More information

UMBILICAL CORD BLOOD COLLECTION

UMBILICAL CORD BLOOD COLLECTION UMBILICAL CORD BLOOD COLLECTION by Frances Verter, PhD Founder & Director, Parent's Guide to Cord Blood Foundation info@parentsguidecordblood.org and Kim Petrella, RN Department of Obstetrics and Gynecology

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll

More information